Precious Cat Donates November Sales To Cancer Research

To support Pet Cancer Awareness Month in November, Precious Cat Inc. will donate 100% of November sales to help fight cancer.

Precious Cat and the Multiple Myeloma Research Foundation (MMRF) announced a new partnership to accelerate the development of new treatments for multiple myeloma, an incurable blood cancer. During the month of November, Precious Cat will donate 100% of all sales from its cat litter to the MMRF, one of the nation’s leading cancer research organizations and a driving force behind progress made against multiple myeloma. 

"We are grateful to Precious Cat’s support of multiple myeloma research," said Kathy Giusti, Founder and CEO of the MMRF and a multiple myeloma patient. "Innovative partnerships with companies like Precious Cat will sustain our urgent work to bring patients new, life-extending treatments, many of which may be used to treat other cancers. In fact, today’s standard therapies for multiple myeloma, including Velcade® (bortezomib) and Revlimid® (lenalidomide), which the MMRF helped to bring to market, are benefiting thousands of other cancer patients."

Precious Cat was founded by Dr. Bruce Elsey, a veterinarian specializing in feline medicine, and Kathy Elsey, a myeloma patient. Since Kathy’s diagnosis with multiple myeloma less than 2 years ago, the Elsey’s have personally donated more than $2 million to fund the MMRF’s drug discovery initiatives and clinical trial consortium dedicated to rapidly advancing new therapies for patients.

"Given the MMRF’s track record in helping to bring four new drugs to patients, we strongly believe in their ability to bring patients the next generation of treatments," said Dr. Elsey. "We are proud to partner with them to advance their cutting-edge research portfolio and are excited to offer all cat owners the opportunity to also support cancer research."

This news story is independently sourced and PetPeoplesPlace.com does not specifically endorse products or services offered by any company referenced in this article, or benefit from any association with any companies referenced.
EPN